BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25585100)

  • 1. Pancreatic cancer, treatment options, and GI-4000.
    Hartley ML; Bade NA; Prins PA; Ampie L; Marshall JL
    Hum Vaccin Immunother; 2014; 10(11):3347-53. PubMed ID: 25585100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic cancer, treatment options, and GI-4000.
    Hartley ML; Bade NA; Prins PA; Ampie L; Marshall JL
    Hum Vaccin Immunother; 2015; 11(4):931-7. PubMed ID: 25933185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
    Amedei A; Niccolai E; Prisco D
    Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
    Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
    J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Probability of vaccine therapy for pancreas cancer].
    Takahashi M; Togou S; Yamaoka H; Ichikawa H; Shimada H; Cheever MA
    Gan To Kagaku Ryoho; 1996 Oct; 23(12):1676-8. PubMed ID: 8886043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutated Ras peptides as vaccines in immunotherapy of cancer.
    Gjertsen MK; Gaudernack G
    Vox Sang; 1998; 74 Suppl 2():489-95. PubMed ID: 9704487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
    Ibrahim AM; Wang YH
    World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes.
    Suso EM; Dueland S; Rasmussen AM; Vetrhus T; Aamdal S; Kvalheim G; Gaudernack G
    Cancer Immunol Immunother; 2011 Jun; 60(6):809-18. PubMed ID: 21365467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New targeted therapies in pancreatic cancer.
    Seicean A; Petrusel L; Seicean R
    World J Gastroenterol; 2015 May; 21(20):6127-45. PubMed ID: 26034349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells.
    Stift A; Friedl J; Dubsky P; Bachleitner-Hofmann T; Benkoe T; Brostjan C; Jakesz R; Gnant M
    Int J Oncol; 2003 Mar; 22(3):651-6. PubMed ID: 12579320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
    Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH
    BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.
    Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E
    Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation.
    Gjertsen MK; Bakka A; Breivik J; Saeterdal I; Solheim BG; Søreide O; Thorsby E; Gaudernack G
    Lancet; 1995 Nov; 346(8987):1399-400. PubMed ID: 7475823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing the course of pancreatic cancer--Focus on recent translational advances.
    Javle M; Golan T; Maitra A
    Cancer Treat Rev; 2016 Mar; 44():17-25. PubMed ID: 26924195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.
    Garrido-Laguna I; Hidalgo M
    Nat Rev Clin Oncol; 2015 Jun; 12(6):319-34. PubMed ID: 25824606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor specific CD8+ T cells in patients with lung cancer and healthy individuals.
    Karanikas V; Germenis A
    J BUON; 2009 Sep; 14 Suppl 1():S153-7. PubMed ID: 19785058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express α-gal epitopes.
    Furukawa K; Tanemura M; Miyoshi E; Eguchi H; Nagano H; Matsunami K; Nagaoka S; Yamada D; Asaoka T; Noda T; Wada H; Kawamoto K; Goto K; Taniyama K; Mori M; Doki Y
    PLoS One; 2017; 12(10):e0184901. PubMed ID: 29077749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pancreatic cancer vaccines could unleash the army within.
    Springett GM
    Cancer Control; 2014 Jul; 21(3):242-6. PubMed ID: 24955709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer).
    Yoshimura K; Olino K; Edil BH; Schulick RD; Oka M
    Surg Today; 2010 May; 40(5):404-10. PubMed ID: 20425541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.